Cmed Technology to Preview New Innovations to Speed and Streamline Electronic Trials at DIA Conference

Demonstrations to showcase new Timaeus capabilities for faster study build, earlier go-live dates, more responsive investigator site and monitoring experience

NEW PROVIDENCE, N.J., June 8, 2011 /PRNewswire/ -- Cmed Technology, an innovative provider of eClinical technology, announced today it will preview its forthcoming Timaeus Guided Trial Builder product at this month's Drug Information Association (DIA) Annual Meeting in Chicago, IL. Guided Trial Builder will introduce an entirely different approach to simplify and streamline the startup of electronic trials. It expands on the Timaeus on-demand eClinical platform's history of harnessing innovation to empower clinical research teams to do more-in more places-with less time and effort.

Guided Trial Builder will enable non-programmers to rapidly build entire trials, including visit schedules, pages and edit checks. It automatically ensures adherence to standards and seamlessly validates the trial during the build process, eliminating the need for manual quality control (QC) and hand-off between teams. Adding Guided Trial Builder to Timaeus' on-demand deployment capabilities allows study teams to start new trials and perform mid-trial updates at the touch of a button-without downtime or site interruption. Cmed Technology is currently working with a Top 10 pharmaceutical company to quantify the time and efficiency improvements Guided Trial Builder will provide.

"Today, more than ever, speed is everything as pharmaceutical and biotech companies look for faster trial builds, earlier go-live dates and immediate access to clinical trial data," said Dr. David Connelly, CEO of Cmed. "Guided Trial Builder expands on our many years of work building eClinical technology that can rapidly respond to the needs of research organizations. Imagine the benefits of building and deploying entire study databases in days-rather than weeks or months."

Cmed Technology will highlight how Timaeus 5 benefits various clinical trial roles at its DIA Booth 1662. Visitors will be able to build, immediately deploy and conduct user acceptance testing (UAT) on trials themselves. They will be able to capture data, perform source data verification (SDV) and run real-time reports using Timaeus Web. They also can explore a fast, reliable and secure mobile experience using the Apple iPad® with Timaeus HotSpot, the industry's first portable eClinical suite. To schedule a demonstration, please send an email to [email protected] or register online at www.cmedtechnology.com/dia.

About Cmed Technology

Cmed Technology is an innovative provider of eClinical technology and solutions. Its unified eClinical platform, Timaeus, combines advanced distributed cloud, mobile and tablet computing technologies to provide research organizations the freedom to manage any type of data, for any trial, anywhere. Created in 2002, Timaeus has been used by biopharmaceutical companies, non-profit institutions, CROs and other research organizations for early phase, pivotal and late phase studies. Timaeus provides on-demand solutions for programming of simple, complex and adaptive trials (Timaeus Trial Builder); electronic data capture (Timaeus Electronic Data Capture); monitoring (Timaeus Field Monitoring); in-stream coding (Timaeus Medical Coding); electronic, paper, and hybrid trial data management (Timaeus Electronic Data Management); and clinical and operational reporting (Timaeus Reporting). A division of the Cmed Group with roots from the University of Oxford, Cmed Technology has offices in the United Kingdom, the United States and Romania. To learn more, visit http://www.cmedtechnology.com.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.